Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 18/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210112 | 0.82 | AHR (1.00) | AHR | |
| SCHEMBL6468484 | 0.78 | AHR (0.67) | AHRCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL22815436 | 0.76 | AHR (0.60) | AHR | |
| SCHEMBL1804174 | 0.76 | AHR (1.00) | AHRCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6466778 | 0.74 | AHR (0.73) | AHRMCL1 | |
| SCHEMBL8952247 | 0.74 | AHR (0.73) | AHRMCL1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13672099 | 0.74 | AHR (0.73) | AHRMCL1 | |
| SCHEMBL6466427 | 0.73 | AHR (0.76) | AHR | |
| SCHEMBL2281485 | 0.72 | AHR (1.00) | AHR | |
| SCHEMBL29349569 | 0.72 | AHR (1.00) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608306-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050143450-A1 | Alkyl PCDF as a treatment for prostate cancer | TEXAS A&M UNIVERSITY SYSTEM (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005032452-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1140047-B1 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | TEXAS A & M UNIV SYS (US) | 2003-10-29 | — | — | EP | claimed |
| EP-1140047-A2 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2001-10-10 | — | — | EP | claimed |
| US-6136845-A | ANTITUMOR AGENTS; MIXTURE CONTAINING POLYCHLORINATED DIBENZOFURAN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2000-10-24 | — | — | US | claimed |
| WO-2000037065-A2 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2000-06-29 | — | — | WO | claimed |
| US-5516790-A | Synthesis and application of alkyl-substituted dibenzofurans as antitumorigenic agents | TEXAS A&M UNIVERSITY SYSTEM TECHNOLOGY LICENSING OFFICE (US) | 1996-05-14 | — | — | US | claimed |
| EP-1608306-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050143450-A1 | Alkyl PCDF as a treatment for prostate cancer | TEXAS A&M UNIVERSITY SYSTEM (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005032452-A2 | ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER | TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1140047-B1 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | TEXAS A & M UNIV SYS (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1140047-A2 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6136845-A | ANTITUMOR AGENTS; MIXTURE CONTAINING POLYCHLORINATED DIBENZOFURAN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2000-10-24 | — | — | US | disclosed |
| WO-2000037065-A2 | ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143450-A1 | Alkyl PCDF as a treatment for prostate cancer | KLK3, ACP3, AR | AHR 379/4885MCL1 200/4885CSNK2A2 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.